- Home
- ARBE vs IMAB Comparison
ARBE vs IMAB Comparison
Compare ARBE & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBE
- IMAB
- Stock Information
- Founded
- ARBE 2015
- IMAB 2014
- Country
- ARBE Israel
- IMAB United States
- Employees
- ARBE N/A
- IMAB N/A
- Industry
- ARBE EDP Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ARBE Technology
- IMAB Health Care
- Exchange
- ARBE Nasdaq
- IMAB Nasdaq
- Market Cap
- ARBE 161.8M
- IMAB 83.8M
- IPO Year
- ARBE N/A
- IMAB 2020
- Fundamental
- Price
- ARBE $1.93
- IMAB $1.07
- Analyst Decision
- ARBE Strong Buy
- IMAB Strong Buy
- Analyst Count
- ARBE 2
- IMAB 3
- Target Price
- ARBE $3.00
- IMAB $8.00
- AVG Volume (30 Days)
- ARBE 55.0K
- IMAB 188.0K
- Earning Date
- ARBE 11-06-2024
- IMAB 08-28-2024
- Dividend Yield
- ARBE N/A
- IMAB N/A
- EPS Growth
- ARBE N/A
- IMAB N/A
- EPS
- ARBE N/A
- IMAB N/A
- Revenue
- ARBE $1,372,000.00
- IMAB $3,492,091.00
- Revenue This Year
- ARBE $1.56
- IMAB N/A
- Revenue Next Year
- ARBE $1,875.55
- IMAB N/A
- P/E Ratio
- ARBE N/A
- IMAB N/A
- Revenue Growth
- ARBE N/A
- IMAB N/A
- 52 Week Low
- ARBE $1.40
- IMAB $0.99
- 52 Week High
- ARBE $2.59
- IMAB $2.54
- Technical
- Relative Strength Index (RSI)
- ARBE 43.08
- IMAB 40.39
- Support Level
- ARBE $1.80
- IMAB $1.03
- Resistance Level
- ARBE $1.97
- IMAB $1.26
- Average True Range (ATR)
- ARBE 0.07
- IMAB 0.09
- MACD
- ARBE -0.00
- IMAB 0.01
- Stochastic Oscillator
- ARBE 59.70
- IMAB 12.82
About ARBE Arbe Robotics Ltd.
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, USA, and others.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).